Allergan CEO: Emerging Customers | Mad Money | CNBC

Allergan reported terrific earnings, but the stock remained stagnant. Is the Botox-maker frozen, or is now the time to buy? Jim Cramer eyed the fine lines of its latest earnings report with the CEO.
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
» Read more about Allergan here: http://cnb.cx/2vgbvsn
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.

About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.

Get More Mad Money!
Read the latest news: http://madmoney.cnbc.com
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer

Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC

Allergan CEO: Emerging Customers | Mad Money | CNBC



(Source: CNBC (via YouTube))